Business
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD
March 31, 2026
The Motley Fool
Scroll
This specialty pharma firm focused on pain management therapies reported a notable insider sale amid steady revenue and recent stock gains.
The Motley Fool
Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.
United States of America
Bias: lean left